Rapid antidepressant effects: moving right along
K Martinowich, D V Jimenez, C A Zarate Jr, H K Manji, K Martinowich, D V Jimenez, C A Zarate Jr, H K Manji
Abstract
Available treatments for depression have significant limitations, including low response rates and substantial lag times for response. Reports of rapid antidepressant effects of a number of compounds, including the glutamate N-methyl-D-aspartate receptor antagonist ketamine, have spurred renewed translational neuroscience efforts aimed at elucidating the molecular and cellular mechanisms of action that result in rapid therapeutic response. This perspective provides an overview of recent advances utilizing compounds with rapid-acting antidepressant effects, discusses potential mechanism of action and provides a framework for future research directions aimed at developing safe, efficacious antidepressants that achieve satisfactory remission not only by working rapidly but also by providing a sustained response.
Conflict of interest statement
CONFLICT OF INTEREST
KM and DVJ are currently full-time employees of the Lieber Institute for Brain Development, CAZ is currently a full-time employee of the intramural program of the National Institute of Mental Health and HKM is currently a full-time employee of Janssen Research and Development, LLC. We declare that, except for income received from their primary employers, no financial support or compensation has been received from any individual or corporate entity for research or professional service and there are no real or perceived financial holdings that could be perceived as constituting a potential conflict of interest. CAZ and HKM are listed as co-inventors on a patent application for the use of ketamine in major depression. CAZ and HKM have assigned their rights on the patent to the US government but may share a percentage of any royalties that may be received by the government. HKM, however, will waive any such royalties that may be received in relation to this patent application.
Figures
Source: PubMed